Table 1.
Baseline characteristics of patients included in the study
Placebo MP p test
n 38 34
Age (mean (SD)) 58.12 (14.01) 58.55 (13.16) 0.894
Gender = male (%) 24 (63.2) 26 (76.5) 0.333
Race (%) 0.405
Caucasian 22 (57.9) 21 (61.8)
Latino 15 (39.5) 10 (29.4)
Others 1 ( 2.6) 3 ( 8.8)
Body mass index (median [IQR]) 27.70 [25.10, 31.44] 28.95 [27.14, 30.25] 0.315 nonnorm
Smoking status (%) 0.363
Current smoker 2 ( 5.3) 0 ( 0.0)
Never smoker 24 (63.2) 21 (61.8)
Previous smoker 12 (31.6) 13 (38.2)
Arterial hypertension = si (%) 12 (31.6) 11 (32.4) 1.000
Diabetes mellitus (%) 0.229
NA 1 ( 2.6) 0 ( 0.0)
no 33 (86.8) 26 (76.5)
si 4 (10.5) 8 (23.5)
Respiratory disease (%) 0.364
No 34 (89.5) 32 (94.1)
COPD 0 ( 0.0) 1 ( 2.9)
Asthma 2 ( 5.3) 0 ( 0.0)
Other 2 ( 5.3) 1 ( 2.9)
Charlson index (median [IQR]) 0.00 [0.00, 1.00] 0.00 [0.00, 1.00] 0.396 nonnorm
Oral antidiabetics = si (%) 5 (13.2) 6 (17.6) 0.841
Insulin = si (%) 2 ( 5.3) 3 ( 8.8) 0.897
ACEI = si (%) 4 (10.5) 3 ( 8.8) 1.000
ARB = si (%) 5 (13.2) 4 (11.8) 1.000
Inhaled corticosteroids = si (%) 2 ( 5.3) 0 ( 0.0) 0.523
Hydroxichloroquine = si (%) 1 ( 2.7) 4 (11.8) 0.305
Time from symptom onset (median [IQR]) 9.00 [8.00, 11.00] 9.00 [7.00, 10.00] 0.135 nonnorm
SAFI (median [IQR]) 452.38 [447.62, 457.14] 452.38 [452.38, 457.14] 0.890 nonnorm
Findings on chest RX (%) 0.956
Bilobar pneumonia 15 (39.5) 12 (35.3)
Consolidations 1 ( 2.6) 1 ( 2.9)
Lobar pneumonia 6 (15.8) 7 (20.6)
Multilobar pneumonia 16 (42.1) 14 (41.2)
Limphocytes (median [IQR]) 1,200.00 [1,000.00, 1,475.00] 1,110.00 [802.50, 1,600.00] 0.765 nonnorm
C-reactive protein (median [IQR]) 97.89 [71.56, 132.17] 92.70 [66.09, 120.85] 0.701 nonnorm
Ferritin (median [IQR]) 785.50 [413.88, 1,176.68] 737.00 [391.52, 1,147.15] 0.720 nonnorm
IL-6 (median [IQR]) 29.15 [15.80, 48.10] 34.80 [20.00, 48.40] 0.669 nonnorm
Lactate dehydrogenase (median [IQR]) 301.10 [255.25, 356.70] 294.50 [264.00, 367.50] 0.795 nonnorm
D-dimer (median [IQR]) 557.00 [407.75, 724.50] 630.00 [428.00, 930.00] 0.530 nonnorm